PubMed · 15962522
Azacitidine.
Abstract
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Jean-Pierre Issa, Hagop Kantarjian. 2005. Azacitidine.. https://doi.org/10.1038/nrd1726. https://searchpubmed.org/record/pubmed%3A15962522/azacitidine
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite Search PubMed by Indiciae: BibTeX · RIS.